BTIG raised the firm’s price target on Glaukos (GKOS) to $131 from $123 and keeps a Buy rating on the shares after the company announced FDA approval allowing for repeat treatments of iDose. Glaukos now has a much broader label for iDose than the prior label, which was limited to one iDose per eye, the analyst tells investors in a research note. BTIG believes the approval gives the company “significant optionality” in the interventional glaucoma space.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Wells sees potential upside after Glaukos’ iDose repeat dosing label approved
- Glaukos announces FDA approval of iDose TR NDA labeling supplement
- Glaukos price target raised to $160 from $115 at Stifel
- Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors
- Glaukos falls -8.5%